The hematological parameters and serum biomarkers of inflammation and immunity in patients with atopic dermatitis and psoriasis.
Apilimod mesylate by OrphAI Therapeutics for Amyotrophic Lateral Sclerosis: Likelihood of Approval
Apilimod mesylate is under clinical development by OrphAI Therapeutics and currently in Phase II for Amyotrophic Lateral Sclerosis.